BTOG’s Vision is to ensure equitable access to optimal care for patients with all thoracic malignancies in the UK and Ireland.

BTOG’s Mission is to support and educate healthcare professionals, creating a professional community to exchange ideas, information and innovation and to foster the development of research. The overall aim is to represent the needs of patients and improve their outcomes.

Opening Message from the BTOG Steering Committee Chair

BTOG has been exceptionally busy during this year. Highlights have included the development and launch of the new logo, website and member resources.

The original logo was created in 2002 and we tried to remain sympathetic to the original whilst bringing it up to date and creating a stronger visual identity.

Towards the end of this year we launched the new website with improved membership resources. These developments represented a significant amount of commitment and work for the BTOG team – the BTOG Steering Committee, Board of Trustees and Business Manager and for BTOG’s Communication Associates.

BTOG continues to develop robust governance with the introduction of an extensive policy portfolio.

Strategic planning is high on the agenda to ensure that what BTOG does is informed, relevant and funded.
**BTOG’s Key Activities**

The BTOG Steering Committee represent the multi-disciplinary team, support the aims and objectives of BTOG and take an active role in education and representation.

https://www.btog.org/home-page/about-btog/meet-the-btog-team/#BTOG-steering-committee

The BTOG Board of Trustees is responsible for safeguarding the values and purpose of BTOG and ensuring that activities contribute to achieving the objects of the charity and that BTOG follows its legal obligations.

https://www.btog.org/home-page/about-btog/meet-the-btog-team/

**BTOG’s Values**

- We are committed to achieving our mission and vision.
- We are proud to be an important part of the thoracic oncology professional community.
- We work collaboratively with other groups who, in their own ways, are also striving to improve outcomes for this group of patients or reduce the prevalence of lung cancer e.g. relating to smoking cessation.
- We listen to our stakeholders to ensure what we do is relevant and effective.
- We maintain a highly professional level of independence from any single external commercial organisation.
- We hold patients at the centre of everything we do.
Education

Continuing Professional Development – CPD

BTOG provides an annual CPD education programme of value in terms of content and registration fees to the whole multi-disciplinary team (MDT). All programmes are accredited by recognised and relevant bodies.

These events are also accessible to advocates who sit on thoracic oncology clinical studies or trial management groups, advisory boards/groups or other related groups.

Annual Conference:
- The Federation of the Royal Colleges of Physicians of the United Kingdom
- The Royal College of Pathologists
- The Royal College of Surgeons of England
- RCSI Faculty of Radiologists

All Education Events:
- The Federation of the Royal Colleges of Physicians of the United Kingdom

- BTOG Postgraduate Thoracic Oncology Course
  Monday 8th & Tuesday 9th May 2017, Leicester
  “Learned so much. Consolidated knowledge. I would recommend all new staff who work with lung cancer patients to attend course.”
  “Excellent speakers – I feel really motivated and enthused. I have some great ideas to improve/enhance my practice.”

- ASCO 2017 National Update
  BTOG and Roy Castle Lung Cancer Foundation
  Friday 9th June 2017, London
  “Really informative and relevant day.”
  “Excellent talks. I left feeling much more comfortable treating with IOs. Cases very interesting.”

- NCRI and BTOG Lung CSG Annual Trials Meeting
  Friday 16th June 2017, London
  “Very stimulating meeting. Good range of topics.”
  “High quality meeting.”

- BTOG – Immunotherapy 2017 – The Essential Update
  Friday 24th November 2017, London
  “Really informative and relevant day.”
  “Excellent talks. I left feeling much more comfortable treating with IOs. Cases very interesting.”
“Really fantastic MDT meeting”

“I enjoyed all the sessions I attended and feel that my clinic knowledge has been enhanced from attending BTOG”

“Content was interesting and well presented”

“Superb conference; high quality speakers, relevant topics and brilliantly structured”

“The whole organisation of BTOG was brilliant, from the hotel and facilities to the conference and smooth running of the whole event”

“Excellent organisation. I had not been to a conference before that would have its delegates so well looked after”

16th Annual BTOG Conference 2018
Dublin

852 attendees
3 days
89 Speakers & Chairs
25 exhibition stands with over 250 exhibitors
199 posters
179 FIRST TIMERS

Over 3m twitter impressions
48,000 page views on the EVENT APP
2,680 TWEETS using #BTOG2018

Topics Covered
- Translational Oncology
- Respiratory Medicine
- Radiotherapy
- Radiology
- Nursing
- Screening
- Surgery
- Palliative Care
- Immunotherapy
- Neuroendocrine Tumours
- Mesothelioma
- Optimal Lung Cancer Pathway
Research and Representation

The abstracts from BTOG 2018 were published in a Supplement to Lung Cancer journal published by Elsevier.
Reference: Volume 115, Supplement 1, January 2018, ISSN 0169-5002
https://www.sciencedirect.com/journal/lung-cancer/vol/115/suppl/S1

During the year BTOG has provided networking opportunities at all educational events for the professional community to collaborate to develop clinical trials and other research. BTOG has continued to work collaboratively with many other organisations, societies and groups; to build close and enduring relationships; and to have mutual memberships to ensure representation.

The British Thoracic Society (BTS) exists to improve standards of care for people who have respiratory diseases and to support and develop those who provide that care. During this year BTOG and BTS held collaborative sessions at BTS Winter 2017 and BTOG 2018.

European Thoracic Oncology Platform (ETOP) promotes the exchange of ideas and research in the field of thoracic malignancies. During this year BTOG has continued as a member group and Dr Sanjay Popat, BTOG Steering Committee Chair sits on the Foundation Council.

The IASLC has developed a network of Regents around the world to constitute a Council of Regents responsible for a country or group of countries within a geographical region. The Regents have been appointed by the IASLC board to ensure effective communication between IASLC and the members and potential members of the IASLC in the country for which they have responsibility. IASLC currently has Regent Representatives in 17 regions and covering Medical Oncology, Radiation Oncology, Pulmonology, and Thoracic Surgery and Dr Richard Booton, BTOG Steering Committee member is Regent for UK and Ireland.

Professor Michael Peake, BTOG Trustee and Dawn McKinley, BTOG Manager are both Trustees for Mesothelioma UK.

Liz Darlison, Head of Services for Mesothelioma UK and Consultant Nurse for UHL NHS Trust was a BTOG Steering Committee member and now has an Honorary Executive Officer role for BTOG representing UHL NHS Trust.
BTOG and NCRI are both committed to driving and encouraging the development of clinical trials in thoracic oncology. During this year BTOG Steering Committee Member, Dr Matthew Hatton has been Chair of the NCRI Lung Cancer Clinical Studies Group (CSG) and BTOG Steering Committee Chair, Dr Sanjay Popat has been Chair of the NCRI Lung Cancer CSG Advanced Disease Sub-group. The NCRI and BTOG held collaborative sessions at BTOG 2018 to update on progress for each of the Lung Cancer subgroups.

NLCFN provides networking and support to nurses specialising in the care of people with lung cancer and as a multi-disciplinary group, BTOG is committed to including nurses in all that it does. During this year BTOG Steering Committee Members, Helena Stanley and Jackie Fenemore both sat on the NLCFN Committee and Jackie was Vice-Chair/Chair Elect of NLCFN, ensuring mutual representation on both committees.

The Roy Castle Lung Cancer Foundation’s three activities are research, support and prevention. During this year working in partnership, BTOG and RCLCF held an ASCO National Update Meeting – the meeting updated on significant data presented at ASCO 2017 held in Chicago 2-6 June 2017 covering Metastatic NSCLC, Early Lung Cancer, SCLC, Mesothelioma and Thymic Cancers.

Thoracic Alliance for Cancer Trials (TACT) is an international non-profit umbrella organisation for academic groups worldwide, dedicated to thoracic oncology research. As a group that has a focus on, but are not directly involved in, conducting clinical trials in thoracic oncology, BTOG is an observer member group and during this year a BTOG steering committee member attended TACT General Assemblies held at ASCO 2017 in June 2017 and at WCLC 2017 in October 2017.

The UK Mesothelioma Alliance (UKMA) was established in 2017 to bring together mesothelioma stakeholders as one voice to raise awareness of mesothelioma through agreed projects. BTOG is a member of the UKMA and Dawn Mckinley, BTOG Business Manager is the Chair of the UKMA.
Guidelines and Articles

• BTS Guideline for the Investigation and Management of Pleural Mesothelioma
  Professor Corinne Faivre-Finn represented the British Thoracic Oncology Group on the Guideline working group and the document was also circulated for comment to the Steering Committee. BTOG endorsed the Guideline which was published in March 2018.

• Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors - The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC) and the Association for Molecular Pathology (AMP)
  The British Thoracic Oncology Group steering committee took part in the consultation to revise the 2013 Guideline. The Guideline was published in March 2018.
  www.ncbi.nlm.nih.gov/pubmed/29355391

• The Royal College of Pathologists’ Dataset for Histopathological Reporting of Lung Cancer
  The British Thoracic Oncology Group took part in the consultation with publication expected during 2018.

• The Royal College of Pathologists’ Dataset for Thymic Epithelial Tumours
  The British Thoracic Oncology Group took part in the consultation published in October 2017.

• The Royal College of Pathologists’ Dataset for Mesothelioma
  The British Thoracic Oncology Group took part in the consultation published in September 2017.
  www.rcpath.org/profession/publications/cancer-datasets.html

• Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey
  The British Thoracic Oncology Group distributed the survey to BTOG members.
  www.ncbi.nlm.nih.gov/pubmed/29477100

NICE National Institute for Health and Care Excellence

BTOG is a recognised body to review NICE appraisals for new drug therapies for thoracic malignancies. This year has seen a number of NICE appraisals and BTOG actively participated in all relevant scoping and full appraisals. Several BTOG Steering Committee (SC) members and other relevant experts represented BTOG in this key role (the representative is in brackets).

• ID925 Lung cancer (non-small-cell, metastatic, untreated, ALK positive) - alectinib (SC: Tom Newsom-Davis)
• ID970 Atezolizumab – Treating locally advanced or metastatic NSCLC lung cancer after platinum-based chemotherapy (Non-SC: Yvonne Summers)
• ID1005 (TA309) Pemetrexed – For following induction therapy w/pemetrexed/cisplatin non-squamous NSCLC (SC: Sanreen Ahmed)
• ID1098 Lung cancer (non-small-cell, advanced, untreated, ROS1-positive) - crizotinib (SC: Sanjay Popat)
• ID1143 Lung cancer (non-small-cell, EGFR positive, ALK negative, untreated) - durvalumab (with tremelimumab)
• ID1175 Lung cancer (non-small-cell, unresectable) - durvalumab (maintenance, after chemoradiation) (SC: Matthew Hatton)
• ID1247 Lung cancer (non-small-cell, untreated, PD-L1) - pembrolizumab (SC: Samreen Ahmed)
• ID1288 Lung cancer (small-cell) - rovalpituzumab tesirine (after 2 therapies)
• ID1302 Lung cancer (non-small-cell, untreated, EGFR-positive) - osimertinib (SC: Tom Newsom-Davis)
• ID1328 Lung cancer (non-small-cell, metastatic, ALK positive) - brigatinib (after crizotinib) (SC: Sanjay Popat)
• ID1349 Lung cancer (non-small-cell, metastatic, untreated, PD-L1) – pembrolizumab (CDF Review of TA447) (SC: Jason Lester)
During this year BTOG sent regular E-News bulletins to BTOG members and other contacts.

BTOG E-News includes information about upcoming BTOG educational events as well as articles of interest, thoracic oncology guidance and reports, and the chance to participate in relevant research and therefore to influence thoracic oncology treatment and care.

During this year BTOG has developed improved member resources for BTOG members including a document library with presentations and videos from BTOG educational events.

The British Thoracic Oncology Group (BTOG) is the multi-disciplinary group for healthcare professionals involved with thoracic malignancies throughout the UK and Ireland.

JOIN NOW
Learn about the benefits of your FREE membership

www.btog.org/home-page/join-btog/